SABCS 2025 – Dr. Erika Hamilton on HER2CLIMB-05 Maintenance

Dr. Erika Hamilton discusses HER2CLIMB-05 from SABCS 2025, showing that tucatinib added to first-line HP maintenance significantly improved PFS in HER2-positive metastatic breast cancer, offering a new maintenance option for HR-negative disease and an alternative for HR-positive disease.